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Disruption of podocyte cytoskeletal biomechanics
by dasatinib leads to nephrotoxicity
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Nephrotoxicity is a critical adverse event that leads to discontinuation of kinase inhibitor (KI)
treatment. Here we show, through meta-analyses of FDA Adverse Event Reporting System,
that dasatinib is associated with high risk for glomerular toxicity that is uncoupled from
hypertension, suggesting a direct link between dasatinib and podocytes. We further inves-
tigate the cellular effects of dasatinib and other comparable KIs with varying risks of
nephrotoxicity. Dasatinib treated podocytes show significant changes in focal adhesions,
actin cytoskeleton, and morphology that are not observed with other KIs. We use phos-
phoproteomics and kinome profiling to identify the molecular mechanisms of dasatinib-
induced injury to the actin cytoskeleton, and atomic force microscopy to quantify impairment
to cellular biomechanics. Furthermore, chronic administration of dasatinib in mice causes
reversible glomerular dysfunction, loss of stress fibers, and foot process effacement. We
conclude that dasatinib induces nephrotoxicity through altered podocyte actin cytoskeleton,
leading to injurious cellular biomechanics.
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Toxicity of targeted therapeutics, such as protein kinaseinhibitors (KIs), is a growing concern in clinical oncologyas many of these new agents are used as long as clinical
benefits are being observed1. This is particularly important for
chronic kidney disease (CKD) patients since loss of renal function
has been associated with increased prevalence of cancer2, whereby
nephrotoxicity could effectively render targeted treatments inac-
cessible to a particularly susceptible group. Accordingly, under-
standing the mechanisms of toxicity of targeted therapies can be
of great utility in the design of improved drug dosage protocols,
early identification of adverse reactions (ADR), and preliminary
screening of patients that may be susceptible to nephrotoxicity.
Several targeted therapeutics, such as KIs against VEGF receptor,
BRAF, PDL, RANKL, and mTOR (list of all protein names and
acronyms are listed in Supplementary Table 1) have been shown
to have nephrotoxic effects3; however, mechanisms of nephro-
toxicity vary and most of them are not clearly understood.
For example, patients on multi-kinase inhibitors that target
VEGF receptor have increased risk of developing hypertension
along with nephrotic-range proteinuria possibly as a secondary
complication4.
Downing et al. recently published meta-analyses showing that
despite years-long clinical trials, 32% of all new FDA-approved
drugs had post-market safety events, resulting in withdrawals and
black-box warnings within six years of their approval5. This study
showed that both preclinical studies and multiphasic clinical trials
could fail to identify serious ADR of new drugs, in particular
those effects that could develop over long periods of time, such as
CKD. This is particularly critical in the case of nephrotoxicity
because even subclinical acute injuries could increase the risk for
developing CKD and other non-renal morbidities later in life6.
In the current study, we therefore analyze patient ADR reports,
including post-marketing data, to quantify the relative risk for
nephrotoxicity in cancer patients that received treatment with
KIs. We show that BCR-ABL1 inhibitor dasatinib used for
chronic myeloid leukemia (CML), has the highest reporting
odds ratio for nephrotoxic ADR with no apparent increase of
hypertension risk. Using an integrative approach that includes
high-throughput imaging, single-cell analytics, and phosphopro-
teomics, we identify the cellular, molecular, and biophysical
characteristics of dasatinib-associated nephrotoxicity and further
highlight the potential mechanisms that lead to podocyte
pathophysiology and glomerular dysfunction both in vitro and
in vivo. Our results comprise quantitative characterization of
dasatinib-induced nephrotoxicity, linking molecular processes
and the associated biophysical changes with clinical phenotype.
They further provide a framework for future studies to identify
off-target renal effects and offer a mechanism that can be used in
early drug development and safety studies. We also identify a
non-hypertension inducing nephrotoxic KI that leads to glo-
merular damage instead of acute tubular injury. Additionally, we
show that perturbations with even mild cytoskeletal effects may
have a substantial impact on glomerular physiology, further
highlighting a previously overlooked relationship between mul-
tiple subthreshold acute injuries and development of CKD later
in life.
Results
Dasatinib associates with renal injury but not hypertension.
We previously reported a crowd-sourcing approach to rank drug
associated ADR in the FDA Adverse Event Reporting System
(FAERS) database7. Our data mining approach (Fig. 1a) showed
that various KIs exhibit significantly increased reporting odds
ratios (RORs) for nephrotoxic ADR, which have been unobserved
or under-reported before. Along with VEGF receptor inhibitors
axitinib, sorafenib and sunitinib, dasatinib showed a high risk for
nephropathies compared to other KIs (Fig. 1b). When we further
dissected subcategories of ADR, we noted that while dasatinib
had one of the highest RORs for glomerular events, it ranked
among the lowest for tubular events (Supplementary Fig. 1).
Dasatinib is a multi-kinase inhibitor targeting ABL1, SRC, and
LCK8. While there was a number of other KIs that had similar
target profiles (such as bosutinib and nilotinib), none of these
ranked as high as dasatinib, suggesting that another off-target
kinase (or a combination) was responsible for the renal ADR.
Previously, a few case reports have noted nephrotic-range pro-
teinuria on dasatinib patients that was attributed to its inhibitory
effect on VEGF receptor9 as VEGF receptor inhibitors have
been shown to induce renal ADR associated with vascular toxicity
and hypertension10 with secondary renal dysfunction4. To test
the connection between dasatinib-induced hypertension and
nephrotic syndrome, we determined the correlation between
RORs for hypertension and nephrotoxicity for FDA-approved
KIs. As expected, the two risk factors for most of the KIs showed
a strong correlation, where an increased ROR for hypertension
was accompanied by an increased ROR for glomerular injury
(Fig. 1c). We note that dasatinib did not cluster with any of the
VEGF receptor inhibitors that showed high risk for hypertension.
In fact, it was completely outside the observed correlative
relationship between the two risk factors with one of the highest
observed odds ratio for nephrotic syndrome and a relatively
low risk for hypertension. This finding suggested that the
nephrotoxicity of dasatinib was primarily through its effect on
glomerular podocytes and independent of systemic or glomerular
VEGF inhibition.
Dasatinib disrupts actin cytoskeleton and FA architecture. To
experimentally test the hypothesis that the nephrotoxic outcome
for dasatinib was through its effect on podocytes, we performed
immunofluorescence-based high-content image analysis (HCA)
coupled with quantitative single-cell morphometry on podocytes
treated with KIs that represented varying ROR scores from the
data-mining results (Supplementary Fig. 1). We hypothesized that
among the three constituent cell types of the glomerular filtration
barrier, (i.e., endothelial cells, mesangial cells, and podocytes), KIs
would most significantly impact podocytes because of their highly
elaborate and specialized cytoskeletal architecture. Differentiated
immortalized mouse podocytes, which have been shown to
recapitulate podocyte injury in vivo11, were treated with KIs
representative of various targets: BCR-ABL1 inhibitors dasatinib
(DAS), imatinib (IMA), nilotinib (NIL), bosutinib (BOS), the
VEGF receptor inhibitor vandetanib (VAN), and EGF receptor
inhibitor erlotinib (ERL). Key metrics and pharmacological
information for the selected drugs are summarized in Supple-
mentary Table 2.
Shown in Fig. 2a are representative images of podocytes that
were treated with 2 µM KIs for 1-h and stained with phalloidin,
anti-actinin-4 and anti-paxillin antibodies, and Hoechst 33342 to
visualize F-Actin, crosslinked podocyte-specific stress fibers, focal
adhesions (FA), and nuclei, respectively. Qualitatively, podocytes
treated with dasatinib showed a marked decrease in cell-to-cell
contacts, cell size and number of FA. To quantitatively determine
the effect of KI treatment on podocyte phenotype, we quantified
podocyte cell and nuclear morphology, actin fiber organization
and FA characteristics using high-content image analysis (HCA;
Supplementary Fig. 2). Over 60 nuclear and cell features were
extracted from cells stained for nuclear, focal adhesion and
cytoskeletal markers; features included cellular and nuclear size,
aspect ratio, stress fiber characteristics, and FA size and number.
Compared to control, dasatinib treated cells had significantly
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smaller cell spreading area (Fig. 2b), with the highest decrease
observed among all other KIs (three replicates, ***p < 0.001,
nonparametric Kruskal-wallis one-way ANOVA, followed by
Tukey post-hoc multiple comparison against control). There was
also significant reduction in normalized mean actin intensity for
dasatinib treated cells, while erlotinib had a significant increase
suggesting an enhancement of cytoskeletal stability by EGF
receptor inhibition, as noted by others12,13. A similar effect was
observed in nuclear size and shape and YAP nuclear localization
(Fig. 2c). Number and size of actin stress fibers and colocalization
of α-actinin-4 with F-actin (Fig. 2d) decreased significantly only
in the dasatinib group, concordant with the observed actin
cytoskeletal and FA disruption. Dasatinib treated podocytes also
showed significantly lower number of FA per cell compared to
control (Fig. 2e), with concomitant decrease in colocalization
of actin-crosslinker α-actinin-4. Surprisingly, other BCR-ABL1
inhibitors, including first generation inhibitor imatinib, as well as
VEGF receptor inhibitor vandetanib whose downstream effector
SRC could affect FA, did not markedly impact the cytoskeletal
and FA integrity of podocytes. When the median values for all of
the quantified cellular, nuclear, cytoskeletal, and focal adhesion
morphometric parameters for different conditions are compared
using unsupervised clustering with Euclidean distance, dasatinib
showed a clear separation from all other conditions (Fig. 2f). This
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Fig. 1 Mining of the FDA Adverse Reporting System (FAERS) database demonstrates that dasatinib is associated with high risk for nephrotoxicity.
a Workflow for FAERS database mining. b Dasatinib ranked as one of the highest reporting odds ratio (ROR) for all nephropathies among other KIs in the
FAERS database. c When the KI ROR values for glomerular specific nephropathies are plotted against those for hypertension, dasatinib is seen as a clear
outlier with high risk for glomerular disorder and a relatively low risk for hypertension
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suggests that the cytoskeletal disruption mediated by dasatinib
may not be attributed to its inhibition of BCR-ABL1 activity, but
may be due to off-target actin-stabilizing kinases. Furthermore,
failure of vandetanib to phenocopy the actin-disrupted phenotype
of dasatinib treated podocytes suggests that nephrotic syndrome
induced by dasatinib is unlikely to stem from VEGF receptor
inhibition. Lastly, bosutinib, a potent SRC inhibitor, did not
disrupt cytoskeletal and FA integrity of podocytes suggesting that
SRC inhibition was not sufficient to phenocopy the cytoskeletal
disruption observed under dasatinib, although causing similar
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decrease in cell viability (Supplementary Fig. 3). We confirmed
that SRC activity was selectively inhibited by both bosutinib and
dasatinib via western blots (Fig. 3a).
We further performed expansive timecourse studies to
quantify the cellular and nuclear morphometric remodeling
following 30 min to 48 h of drug treatment with all the KIs at
both 100 nM and 2 µM concentrations; the most important
morphometric features are shown in Supplementary Fig. 4-7.
We note that the effects of dasatinib on cell shape, actin stress
fiber formation, and YAP localization were all observed at the
clinically relevant lower concentration of 100 nM (Supplemen-
tary Fig. 6-7). Even though dasatinib’s effect was greatest,
significant perturbations in cell and nuclear size and shape were
observed in most KI-treated cells compared to the control
(vehicle-treated) cells within 1 h of drug treatment. Interest-
ingly, some of the significant morphological changes induced by
the KIs disappeared after 48 h, suggesting that the changes
observed after one-hour signify acute short-term effects, as cells
Fig. 2 Podocyte morphometrics show that focal adhesion architecture and stress fiber formation are severely impacted by dasatinib. a Conditionally
immortalized differentiated podocytes treated for one-hour with 2 µM kinase inhibitor were stained for F-actin (phalloidin), α-actinin-4, paxillin, and nuclei
(Hoechst 33342) to assess cytoskeletal and focal adhesion architecture (scale bars= 50 µm). Scatter plots of b cell size, shape, and average actin
intensity; c nuclear size, shape, and nuclear YAP localization; d stress fiber count per cell, stress fiber area, and F-actin+ actinin-4 colocalization;
e and focal adhesion number per cell and F-actin+ actinin-4 colocalization at the focal adhesion sites in podocytes treated with KIs for 24 h. Central
bullseye within the distributions highlight population medians, boxes highlight the middle quartiles. Sample sizes are nCTRL= 2313; nDAS= 491; nIMA= 1011;
nNIL= 956; nVAN= 788; nERL= 867; and nBOS= 749 for cellular and nuclear plots, which were captured at 200× magnification. Focal adhesion and stress
fiber analysis was performed with images captured at 400× magnification, which had the following sample sizes: nCTRL= 425; nDAS= 221; nIMA= 183;
nNIL= 231; nVAN= 220; nERL= 227; and nBOS= 196. All experimental groups were taken from minimum of three wells of a 96-well plate (***p < 0.001,
Kruskal–Wallis one-way ANOVA followed by Tukey post-hoc multiple comparison). f Heatmap representation of all of the analyzed morphometric
parameters (normalized median value plotted; n= 60) showing that dasatinib is strongly separated from all the other KIs in terms of its effect on cellular,
cytoskeletal and nuclear morphology
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post-hoc multiple comparison) both showed small increase in apoptosis, as quantified by levels of cleaved caspase 3 (CC 3); however there were no
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its ability to block this pathway (mean ± SEM; *p < 0.05, unpaired t-test). e Dasatinib had a major effect on podocyte viability after 24 h of treatment, as
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it was not significantly different from other KIs (geometric mean ± geometric SD, p= 0.169, Kruskal–Wallis one-way ANOVA). f Representative cell
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are perturbed from their initial cellular states. After 48 h, lasting
and robust changes in cell and nuclear size and more critically
significant alterations to the cytoskeleton were observed almost
exclusively in the dasatinib group. The unique impact of
dasatinib on cellular morphology was also clearly visualized
when the 60 morphometric parameters from all KI conditions
were clustered using the t-distributed stochastic neighbor
embedding (tSNE) method (Supplementary Fig. 8). HCA
findings were also recapitulated with immortalized human
podocytes, which revealed the same phenotype (actin-disruption
and decreased cell size) when treated with dasatinib, as
compared to other KIs albeit with increased variability
(Supplementary Fig. 9).
Reduced viability and apoptosis follow cytoskeletal damage.
Another potential explanation for the increased risk of glo-
merular toxicity with dasatinib could be reduced viability and
loss of podocytes. To assess whether dasatinib uniquely
impacted cell survival and apoptosis in podocytes, we compared
cleaved caspase 3 (CC3) expression across different KIs via
western blotting. We found that dasatinib marginally increased
apoptosis in podocytes similar to the mild apoptosis observed
with other tested KIs (Fig. 3b). We further confirmed this
finding using two other methods: quantitative high-content
image analysis with CC3 immunofluorescence staining (Fig. 3c)
and flow cytometry-based Annexin V assay (Supplementary
Fig. 10). While all techniques similarly suggested minimal
increase in apoptosis, there were some differences in the exact
amount most likely due to differential sensitivity of the assays
and the timing of apoptosis they measure. Regardless, none of
the assays detected increased apoptosis uniquely in the dasatinib
group. Furthermore, another key pathway necessary for survival,
MAPK signaling, was not uniquely affected by dasatinib either
(Fig. 3d). While dasatinib decreased p-MAPK levels as expected,
MAPK phosphorylation was not impacted solely by dasatinib
but also by VEGF and EGF receptor inhibitors vandetanib and
erlotinib. Taken together, these results suggested that the
cytoskeletal disruption observed in dasatinib samples is not
linked to increased apoptosis.
To quantitatively determine the comparative effect of
dasatinib on viability, we performed the colorimetric MTT
(3-(4, 5-dimethylthiazolyl-2)-2, 5-diphenyltetrazolium bro-
mide) viability assay (n= 4). Accordingly, dasatinib had a
half-maximal effective concentration (EC50) of 253 ± 19 nM
(geometric mean ± geometric SD) on cultured podocytes
(Fig. 3e, f). While this was not a particularly lethal value, we
note that it was still the lowest among all the tested inhibitors,
albeit not statistically significant compared to other KIs (p=
0.169, nonparametric Kruskal–Wallis test). We then performed
a dose-escalating HCA assay to evaluate the changes in
morphological, cytoskeletal and focal adhesion parameters at
different concentrations of dasatinib (Fig. 4). Compared to the
effective kill concentration, dasatinib had a much lower half-
maximal effective concentration for inducing morphological
and cytoskeletal changes. EC50 values for cell shape and
spreading area metrics were between 18.5 and 44.3 nM (Fig. 4a).
We observed that of all the cellular parameters quantified in our
HCA assay, the highest sensitivity to dasatinib was with stress
fiber and FA density. In particular, number of F-actin stress
fibers and FA were significantly reduced at EC50 of 6.1 and 5.9
nM (Fig. 4b, c), respectively, while the EC50 values for nuclear
architecture were between 20.4 and 21.8 nM (Fig. 4d). Con-
sidering clinically measured maximal plasma concentrations of
130 nM14, our results clearly demonstrate that cytoskeleton
disruption, which occurs at much lower concentrations,
precedes potential loss of cell viability, and it is much more
likely to be responsible for the clinical phenotype.
Dasatinib targets actin-related pathways. To have a compre-
hensive understanding of the systems-level impact of dasatinib,
we performed label-free quantitative proteomic analysis that
compares the phosphoproteomes of untreated and dasatinib-
treated podocytes. Podocytes were lysed and prepared for liquid
chromatography followed by tandem mass spectrometry (LC-MS/
MS) following enrichment of tyrosine-phosphorylated proteins
using immunoprecipitation as previously described15. Briefly,
cultured podocytes were treated with dasatinib or vehicle-control
for one-hour and then lysed in immunoprecipitation (IP) lysis
buffer. Tyrosine phosphorylated proteins were pulled down
overnight at 4 °C using anti-mouse ferromagnetic beads that were
pre-coated with mouse anti-phospho-tyrosine primary anti-
bodies. LC-MS/MS analysis was then used to identify the proteins
in IP lysates and quantify their relative abundances based on
label-free spectral counting16. This process resulted in identifi-
cation of 2130 distinct phosphoproteins. Only proteins with at
least two peptides from both dasatinib and control samples were
compared using a multiple hypothesis corrected t-test (Fig. 5a).
Accordingly, the most significantly impacted phosphoprotein was
the FA protein paxillin (18.7 ± 1.2 vs. 3.3 ± 0.6 unique spectra in
CTRL vs. DAS, mean ± SEM, p= 3.3.10−5), which was inde-
pendently recapitulated via subsequent western blotting.
The majority of 76 statistically significant downregulated
proteins were related to regulation of the actin cytoskeleton and
FA (Supplementary Table 3). We used enrichment analysis17 to
identify which signaling pathways and ontology terms were
associated with the phosphoproteins inhibited by dasatinib
treatment in podocytes (Fig. 5b). The ontology term “Protein-
protein interactions in the podocyte” from WikiPathways reached
the highest significance (p= 1.14 × 10-8) consistent with our
hypothesis that the foot processes (FP) and slit diaphragm
architecture in podocytes are impacted by the altered signaling
landscape. The next highest associations were with “Regulation of
actin cytoskeleton” (p= 7.07 × 10−7) and “Focal adhesion” (p=
4.2 × 10−5) from KEGG pathways, highlighting the prominent
role of actin-mediated signaling during dasatinib treatment. Gene
ontology enrichment showed similar findings with “focal
adhesion”, “stress fiber”, and “actin cytoskeleton” ranking as the
highest cellular components. We then used network analysis
whereby intermediate genes from the human interactome were
combined with the 76 significantly downregulated phosphopro-
teins to determine the protein–protein interaction network that is
targeted by dasatinib. Our analysis revealed a single intercon-
nected island with 190 nodes and 741 edges that was also highly
focused on actin regulators and FA/integrin signaling (Fig. 5c;
complete list of nodes are listed in Supplementary Table 4). In
order to test the specificity of this network, we used Monte Carlo
simulations to create background networks from random 76
proteins identified among the original 2130 LC-MS/MS targets.
When compared to these background networks, dasatinib
network was the largest and most interconnected one based on
all measured metrics (Supplementary Fig. 11), confirming that the
phosphoproteomic assay has correctly identified the actin-centric
signaling foci impacted by dasatinib.
LIM kinase pathway is uniquely impacted by dasatinib. While
quantitative phosphoproteomics provided additional confirmation
that the actin cytoskeleton was one of the principal systems-level
targets of dasatinib, it did not identify any specific candidates that
may be responsible for the unique phenotype we observe in
podocytes. For example, kinase enrichment of the downregulated
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phosphoproteins showed that SRC was the highest associated
upstream kinase, most likely due to its over-representation in the
literature. However, looking at SRC activity across different KI
treatments in podocytes showed that bosutinib treatment resulted
in similar levels of inhibition, suggesting that one or more other
upstream signaling pathways must have been exclusively impacted
by dasatinib (but not by other KIs).
In order to identify kinases targeted by dasatinib (compared to
the other tested KIs) for induction of the unique cytoskeletal
phenotype, we used the previously published kinome-profiling
database that quantified the catalytic activity of 300 human
kinases under small molecule inhibition18. When the database
was limited to include kinases that were inhibited >50% by one or
several of these six tested KIs, dasatinib did not have a
Ct
rl-
1
Ct
rl-
2
Ct
rl-
3
D
AS
-1
D
AS
-2
D
AS
-3
0
1
2
3
4
5
e
c
a b
ABL1
ABL2
EPHA3
EPHA5
FES
HCK
LIMK1
LYN
PAK3
PDGFRA
PDGFRB
Ki
na
se
0 25 50 75 100
Residual activity (%)
22 36 47 53 72 82Mean_residual_activity
Kinase inhibitor
Wikipathways
PodNet: protein-protein interactions in the podocyte (Mus musculus, WP2310)
XPodNet - protein-protein interactions in the podocyte expanded by STRING (Mus musculus, WP2309)
Regulation of actin cytoskeleton (Mus musculus, WP523)
Regulation of actin cytoskeleton (Homo sapiens, WP51)
mRNA processing (Mus musculus, WP310)
EGFR1 signaling pathway (Mus musculus, WP572)
mRNA processing (Homo sapiens, WP411)
Primary focal segmental glomerulosclerosis FSGS (Homo sapiens, WP2572)
Focal adhesion (Mus musculus, WP85)
Focal adhesion (Homo sapiens, WP306)
-log10(p-value)
1.0
GO: molecular function
actin binding (GO:0003779)
calmodulin binding (GO:0005516)
actin filament binding (GO:0051015)
protein kinase binding (GO:0019901)
kinase binding (GO:0019900)
vinculin binding (GO:0017166)
protein C-terminus binding (GO:0008022)
actin-dependent ATPase activity (GO:0030898)
extracellular matrix binding (GO:0050840)
ankyrin binding (GO:0030506)
-log10(p-value)
1.0
d
Kinase enrichment analysis
SRC
GSK3B
MAPK1
CDK5
MAPK14
PTK2
AURKB
INSR
PAK1
CDK1
-log10(p-value)
1.0
KEGG pathways
Regulation of actin cytoskeleton (Homo sapiens, hsa04810)
Focal adhesion (Homo sapiens, hsa04510)
Bacterial invasion of epithelial cells (Homo sapiens, hsa05100)
Leukocyte transendothelial migration (Homo sapiens, hsa04670)
Synaptic vesicle cycle (Homo sapiens, hsa04721)
Endocytosis (Homo sapiens, hsa04144)
Salmonella infection (Homo sapiens, hsa05132)
Amoebiasis (Homo sapiens, hsa05146)
Huntington's disease (Homo sapiens, hsa05016)
Endocrine and other factor-regulated calcium reabsorption (Homo sapiens, hsa04961)
-log10(p-value)
1.0
GO: cellular component
focal adhesion (GO:0005925)
actomyosin (GO:0042641)
contractile actin filament bundle (GO:0097517)
stress fiber (GO:0001725)
endolysosome membrane (GO:0036020)
cytoskeleton (GO:0005856)
endocytic vesicle (GO:0030139)
endolysosome (GO:0036019)
actin cytoskeleton (GO:0015629)
clathrin-coated endocytic vesicle membrane (GO:0030669)
-log10(p-value)
1.0
ARCHS4 transcription factors
TEAD1
FOXL1
ZFP91
SMAD3
CREB3L2
CREB3L1
TBX3
ZC3H7B
MET
TEAD3
-log10(p-value)
1.0
Cofilin1
LIMK
Cofilin1
P
Pak1/2Pak1/2
Actin
severing
LIMK
P
P
lo
g(s
pe
ctr
al 
co
un
ts)
p-PAK
PAK
GAPDH
CT
RL
DA
S
IM
A
NIL VA
N
ER
L
BO
S
CT
RL DA
S
IM
A NIL VA
N
ER
L
BO
S
0
1
2
3
p-
PA
K:
PA
K n
o
rm
***
p-LIMK
LIMK
GAPDH
CT
RL
DA
S
IM
A
NIL VA
N
ER
L
BO
S
CT
RL DA
S
IM
A NIL VA
N
ER
L
BO
S
0
1
2
3
p-
LI
M
K:
LI
M
K n
o
rm
p-
co
fili
n:
co
fili
n n
o
rm
**
p-cofilin
Cofilin
GAPDH
CT
RL
DA
S
IM
A
NIL VA
N
ER
L
BO
S
CT
RL DA
S
IM
A NIL VA
N
ER
L
BO
S
0
1
2
3
* *
DAS BOS ERLIMAVANNIL
ARTICLE NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-019-09936-x
8 NATURE COMMUNICATIONS |         (2019) 10:2061 | https://doi.org/10.1038/s41467-019-09936-x | www.nature.com/naturecommunications
particularly different kinase inhibition signature (Supplementary
Fig. 12). Given the experimental findings, we filtered the kinome-
profiling dataset to retain targets that are associated with actin-
related ontological terms as enriched in our proteomic analyses.
We obtained 12 kinases (EPHA5, PDGFRB, PDGFRA, EPHA3,
ABL2, ABL1, HCK, LIMK1, FES, PAK3, LYN, LRRK2) for which
one or more of the six investigated KIs showed relevant inhibitory
activity. Dasatinib showed the highest overall inhibitory affect
(Fig. 5d). Furthermore, we noted that LIM kinase (LIMK1) was
the only kinase that was inhibited by dasatinib alone and not by
any of the other tested KIs, suggesting a potential role in the
observed cytoskeletal phenotype.
LIM kinase is one of the key regulators for the formation and
crosslinking of actin stress fibers through Rac/Cdc42 signaling19.
Both its upstream activator PAK1/2/320 and downstream effector
cofilin21 have been shown to play key roles in maintaining
podocyte FP architecture22,23. To test whether dasatinib uniquely
inhibited LIM kinase along the Rac/Cdc42 pathway, we assayed the
activity of PAK1, LIMK1 and cofilin in podocytes treated with the
panel of six KIs for one hour. Indeed, western blot analysis showed
that phosphorylation levels for both LIMK1 and cofilin-1 were
significantly reduced only in dasatinib treated samples compared to
podocytes treated with other KIs (Fig. 5e). In agreement with the
proteomic enrichment analyses, we saw that PAK1 was also
uniquely reduced in dasatinib treated podocytes, confirming that
upstream regulatory pathways, including Rac/Cdc42 small GTPase
signaling, were downregulated by dasatinib at a systems-level.
Diminished cytoskeletal integrity leads to FP effacement. Given
LIM kinase and cofilin pathway’s direct role in maintaining the
mature podocyte cytoskeleton22, we hypothesized that dasatinib
would diminish the structural integrity of crosslinked stress fibers,
which would lead to reduced biomechanical stiffness or cellular
elasticity. We used our previously reported atomic force micro-
scope (AFM) elastography technique24 to characterize the spatial
distribution of cellular elasticity of podocytes under various KI
treatments (Fig. 6a). As hypothesized, we found that only
podocytes treated with dasatinib exhibited significant and robust
reduction in their mean cellular elasticity (Fig. 6b and Supple-
mentary Fig. 13); no other KI had a significant effect (p < 0.01
dasatinib vs. all other groups, one-way ANOVA with post-hoc
Tukey). We observed that the reduction in depth-dependent
pointwise elasticity was thoroughly evident through the axial
dimension in further agreement with our HCA measurements for
impaired stress fiber architecture (Supplementary Fig. 14). We
also acquired AFM elastography maps with increased resolution
(Supplementary Fig. 15), which when superimposed over
immunostained high-resolution images of the F-actin for control
podocytes, showed clear colocalization of actin stress fibers and
the highly stiff heterogeneous elasticity measurements (Fig. 6c;
left panel). This correlation was completely abolished under
dasatinib treatment, which resulted in homogeneous, weak
elasticity values (Fig. 6c; right panel). These observations also
agreed with the recent reports showing that dasatinib significantly
affected cellular biomechanics and adhesion of BRAF V600E
mutant melanoma A375 cells25.
Our in vitro measurements of reduced cytoskeletal integrity
suggested that chronic administration of dasatinib should induce
foot process effacement in vivo. To test this, 8-week-old wild-type
129S1/SvImJ mice (n= 8, each group) were administered either
with clinically relevant doses of dasatinib or vehicle control once a
day through oral gavage for five weeks. Ultrastructurally,
dasatinib treated mice showed FP effacement (Fig. 6d) and
significant increase in lateral FP width (Fig. 6e). To assess the
integrity of the podocyte actin cytoskeleton in vivo, we used
immufluorescence measurements looking at synaptopodin-
crosslinked actin stress fibers (Fig. 6f). In agreement with the
in vitro observations of a substantial cytoskeletal effect with little
change in cellular viability, we saw significant reduction in
synaptopodin expression in dasatinib treated mice (Fig. 6g) with
no change in podocyte number as quantified by nuclei positive for
the podocyte-specific marker WT1 (Fig. 6h). We also noted that
LIMK1 phosphorylation was reduced, confirming that Rac/Cdc42
pathway was impacted in vivo by dasatinib leading to glomerular
dysfunction (Supplementary Fig. 16). Formalin-fixed paraffin
embedded tissue sections were stained with hematoxylin-eosin
(H&E), Periodic Acid Schiff (PAS) and trichrome and evaluated
by a blinded expert renal pathologist. Histology examination
showed no significant tubular morphology changes or discernable
differences between animals treated with vehicle or dasatinib
(Supplementary Fig. 17a-c). These observations further mirrored
the FAERS risks scores, which suggested relatively low tubular
toxicity for dasatinib. As an in vitro quality control step, we also
performed MTT-based viability assays on cultured mouse tubular
epithelial cells, which showed that dasatinib had an equivalent or
comparable impact on viability of tubular epithelia with respect to
the other KIs tested and that this was similar to that observed on
podocytes (Supplementary Fig. 17D). While there were no
significant tubular effects, some of the mice showed mild and
irregular proteinuria at five weeks, even though the effect was not
significant (Supplementary Fig. 18). The mild injury phenotype
was consistent with clinical observations of general tolerability,
which further suggested that clinical cases might be due to
repeated sub-threshold injury in susceptible patients. To further
test this hypothesis, we chronically administered dasatinib in
lupus nephritis MRL mice, where podocytes have been shown to
display compromised actin cytoskeleton26,27. Accordingly, our
hypothesis would predict that these animals would be more
susceptible to cytoskeletal injury, and thus they would exhibit
markedly increased glomerular dysfunction when challenged by
dasatinib. In fact, when these mice were treated daily with
dasatinib, they developed severe proteinuria within four weeks,
which was completely reversed after a week of suspending drug
administration (Fig. 6i).
Fig. 5 Phosphoproteomics reveal that processes associated with the actin cytoskeleton are specifically perturbed by dasatinib. a Heatmap for spectral
counts of differentially expressed phospho-tyrosine enriched proteins as quantified by LC-MS/MS. Complete list of proteins plotted in the heatmap are
shown in Supplementary Table 3. b Enrichment analyses using Wikipathways, KEGG Pathways and other ontology libraries coherently associate focal
adhesions and the actin cytoskeleton with the differential phosphoproteome. Highest transcriptional enrichment was for TEAD1 suggesting potential
inhibition of the Hippo pathway. c Predicted protein-protein interaction network using the differentially phosphorylated proteins as seed nodes (cyan) and
one intermediate neighbor (yellow) is highly interconnected. Node size signifies connectivity. Complete list of network associated proteins and number of
connections are listed in Supplementary Table 4. d KINOMEscan analysis reveals that the activity of actin-associated kinases are disproportionately
impacted by dasatinib compared to all other tested KIs; in particular LIM kinase (LIMK1) is identified as a kinase that is inhibited exclusively by dasatinib.
e Active phosphorylation of kinases from the Rac/Cdc42 pathway (PAK1/2, LIMK1, and cofilin), after treatment with 2 µM KIs for 1 h, show strong,
exclusive and statistically significant inhibitory effect for dasatinib but none of the other tested KIs
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Discussion
Understanding the mechanisms of drug toxicity is a central
research goal in clinical oncology. The drug effects on cell survival
and proliferation pathways are often considered as key para-
meters when evaluating safety and efficacy. In this study, we use
an integrative approach to show that the impact of a drug on cell
biophysics could also be relevant to understanding its ADR.
Dasatinib, a second-generation BCR-ABL1 inhibitor, destabilizes
the actin cytoskeleton of kidney podocytes through its systems-
level action that includes impairment of FA architecture and
PAK-LIMK signaling. Cytoskeletal damage has been suggested as
a mechanism of drug toxicity as early as 1990s28. While
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cytoskeletal effects of toxins may play a limited role in the sur-
vival of most cell types, actin-associated proteins serve a critical
function in maintenance of the structural integrity of kidney
podocytes29 that have been shown to have exceptionally fragile
cytoskeletal dynamics30; therefore, it is important to examine the
effects of new therapeutics on the podocyte cytoskeleton. Podo-
cytes perform their primary function under constant mechanical
stress; in fact, loss of podocytes due to biomechanical injury has
been suggested as a key metric in disease progression that may be
even more appropriate than proteinuria31. Our findings show that
the direct effect of a toxin on podocyte cytoskeleton could
increase the likelihood of nephrotoxic ADR even in the absence of
other biomechanical risk factors, such as hypertension.
We used the FAERS database to quantify relative risk scores for
glomerulopathies and hypertension associated with kinase inhi-
bitors. The FAERS database has limitations, the most important
limitation being that it does not allow absolute quantification of
ADR risk but only relative to other ADR reported for various
drugs32. In order to make a more controlled within-class com-
parisons, we have chosen to only compare relative ADR risks
among other small molecule KI drugs in the FAERS database.
The obtained RORs served as a starting point to perform the
mechanistic studies described in this report. The absence of an
increase in risk for hypertension in dasatinib patients was one of
the critical observations that suggested a direct link between
podocytes and the nephrotoxic ADR. The disconnect between
increased risk for proteinuria in the absence of increased bio-
mechanical stress supports the hypothesis that podocytes are
structurally weaker and more prone to biophysical damage when
treated with dasatinib, even under normal physiological condi-
tions. Here, we used atomic force microscopy to show that
dasatinib uniquely affected the structural integrity of the podocyte
cytoskeleton leading to decreased cellular elasticity that impacts
its physiological function as a structural member of the filtration
barrier. We also recapitulated this pathophysiological effect
in vivo using chronic administration of dasatinib in mice, which
resulted in dysregulation of the actin cytoskeleton and FP
morphology.
Even though proteinuria was observed in a few patients on the
highest dose of dasatinib during its phase I trial33, at the time of
this study, dasatinib was not considered a nephrotoxic ther-
apeutic. Following its initial FDA approval, case reports of
nephrotic range proteinuria9 and acute renal failure34 had been
presented. The authors of these reports, respectively, postulated
that possible off-target effects of dasatinib against VEGF and
PDGF receptor might be responsible. While dasatinib has mild
inhibitory activity against the PDGF receptor35, we noted that
other KIs with stronger inhibition of either receptor tyrosine
kinases did not affect the adhesion, morphology, or the cytos-
keleton of cultured podocytes. The kinome profiling comparisons
further corroborated these findings, suggesting that none of the
growth factor receptor tyrosine kinases were uniquely affected by
dasatinib (e.g., PDGF receptor activity was inhibited equally by
imatinib and nilotinib; ephrin signaling was equally impacted by
nilotinib and bosutinib; VEGF receptor activity was reduced
mostly by vandetinib followed by bosutinib). Instead, we saw that
kinases associated with the Rac/Cdc42 pathway and actin reg-
ulation were mostly influenced by dasatinib. In particular, we
showed that PAK-LIMK signaling axis was significantly, and
exclusively, impacted by dasatinib leading to reduced cofillin
phosphorylation and actin stress fiber formation.
A healthy actin cytoskeleton is crucial for the maintenance of
morphological and biophysical properties of the eukaryotic cell36.
In addition to its role in structural integrity, actin plays important
roles in mechanosensation37, endocytosis38, and transcriptional
regulation39. Here, we show that dasatinib impacts a vast inter-
connected signaling network that focuses on the control of focal
adhesion architecture and the actin cytoskeleton, which are cri-
tical for podocyte physiology40. It is important to note that the
effect is not singular but at a systems-level. For example, in
addition to the Rac/Cdc42 pathway, dasatinib also had a severe
effect on Hippo signaling, as measured through nuclear YAP
translocation (Supplementary Fig. 19). We recently showed that
regulators of YAP spatial activity, such as KIBRA, play a critical
role in organization of the actin cytoskeleton in podocytes41.
Recently, biomechanical integrity of podocytes had been pro-
posed as a coherent signature that underlies multiple glomerular
disease models42, supporting our hypothesis that drugs that
challenge the actin cytoskeleton architecture in podocytes may
induce glomerular dysfunction and nephrotoxicity. We also note
that while our in vitro assays were extensive, covering a varying
range of time and concentration values for dasatinib and the
other KIs, the dynamics of the podocyte kinome that controls the
actin cytoskeleton is clearly complex, and it needs to be studied in
further detail.
We acknowledge that the in vivo functional effect of dasatinib
in young and healthy wild-type 129S1/SvImJ mice was subtle yet
robust; it was recognizable as consistent major ultrastructural
alterations with little change in proteinuria. This observation also
agreed with prior literature that has showed that in subclinical
phenotypes, such as minimal change disease, ultrastructural
damage to podocyte FP precedes major glomerular dysfunc-
tion43–45. This is also consistent with the odds ratios we have
observed in our clinical meta-analyses and the low number of
nephrotic range proteinuria case studies in the literature. The
nephrotoxic effect of dasatinib at its clinically used doses is clearly
Fig. 6 Dasatinib impacts podocyte biomechanics and induces foot process effacement in vivo. a Representative AFM indentation curves from elastography
measurements of control and dasatinib treated podocytes that were used to quantify the single-cell biomechanical properties show good agreement
between the Hertzian fits and the advance-phase of the raw indentation curves (insets: phase contrast images of representative cells with the
superimposed blue line denoting the probed area; scale bar= 20 µm). b Significant reduction of apparent elastic modulus is observed in dasatinib-treated
podocytes but not in other KI treatments (line: mean; **p < 0.01 dasatinib vs. all other groups, one-way ANOVA with post-hoc Tukey test). c Spatial AFM
elastography maps highlight stiff linear projections that colocalize with the underlying F-actin stress fibers in control but not in dasatinib treated podocytes
suggesting that existing fibers have lost their biomechanical integrity. d Representative TEM images of kidney sections for 129S1/SvImJ mice that have
been treated daily with dasatinib for five weeks (n= 8, each group) show substantial FP effacement. Scale bars are 5000 and 500 nm for the 2000× and
20,000× images, respectively. e Quantification of FP width from TEM images (mean ± SD; ****p < 0.0001, unpaired t-test). f Immunofluorescence analysis
shows that synaptopodin crosslinked actin fibers are reduced in dasatinib treated glomeruli, even though total number of podocytes is unchanged.
Quantification of g synaptopodin (SYNPO) expression (mean ± SD; **p < 0.01, unpaired t-test) and h WT1-positive podocyte count per glomerulus as
determined by WT1-positive cells show that F-actin crosslinking is significantly lower even though the number of podocytes do not change (mean ± SD;
n.s.= not significant, unpaired t-test) in dasatinib treated animals. Scale bars= 10 µm. i 8-week old MRL/MpJ Lupus mice chronically treated with
dasatinib show severe proteinuria within four weeks that recovers within a week upon suspension of treatment (mean ± SEM; ***p < 0.001, two-way
ANOVA with Bonferroni multiple comparison)
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tolerable and non-toxic to the renal tubules; however, it is
imperative to note that (1) susceptible individuals (or those who
are at risk due to environmental factors) may be more likely to
suffer from a cytoskeletal insult, and that (2) even subclinical
impairment of the cytoskeleton increases podocytes’ vulnerability
to further injury. Our results in the lupus mice further support
this second hit hypothesis suggesting that dasatinib induces a
cytoskeletal challenge that critically impacts podocyte function,
but not immediate survival since the massive proteinuria induced
by dasatinib was quickly reversed once treatment was dis-
continued. This is in agreement with case studies that have
observed immediate resolution of proteinuria in patients, where
dasatinib was replaced with another BCR-ABL1 inhibitor9.
It is well known that as podocytes are postmitotic, acute
injuries greatly increase the risk of CKD and other co-
morbidities6 even if they were completely resolved46. Subclinical
nephrotoxicity of dasatinib is particularly important because
CML small-molecule regimens are increasingly becoming chronic
long-term treatments that last for decades. In this regard, these
observations carry additional significance since small subthres-
hold injury sustained during dasatinib treatment may reflect as
increased risk of developing CKD later in life. We therefore
conclude that patients on dasatinib should be routinely checked
for proteinuria and immediately referred for nephrology evalua-
tion if proteinuria is observed.
Methods
Clinical meta-analyses. Adverse event frequencies from the FDA Adverse Event
Reporting System (FAERS) were obtained from the AERSmine resource that
contains a curated version of the FAERS database47. ADR in the FAERS database
are organized according to MedDRA terms48, which belong to a hierarchical
ontology to classify ADR from high-level organs associated with the pathology to
reported low-level specific conditions. Our ADR risk analysis was limited to FDA-
approved protein kinase inhibitors. We downloaded the frequencies of occurrence
of renal ADR for all protein KIs available in FAERS, together with all other fre-
quencies of ADR reported for these KIs between the years 2004–2018. A time-
stamped record of this download to reproduce this analysis was retained and it is
included in Supplementary Data 1 along with the scripts to reproduce this analysis.
Reporting odds ratios (RORs) were then computed for each KI using the frequency
fdt of the ADR of interest (i.e., glomerulonephritis, nephrotic syndrome, hyper-
tension) in patients using the KI of interest, the frequency fdn of any other ADR
occurring in patients using the KI of interest, the frequencies fnt of occurrence of
the ADR of interest (i.e., glomerulonephritis, nephrotic syndrome, hypertension)
for any other protein kinase inhibitor, and the frequency fnn for all other ADR and
all other KIs. The ROR was calculated using
ROR ¼ fdt=fdn
fnt=fnn
; ð1Þ
whereas the standard error (SE) of the log(ROR) was calculated as
SElogðRORÞ ¼
ffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffi
1
fdt
þ 1
fdn
þ 1
fnt
þ 1
fnn
s
; ð2Þ
with the log-transformed 95% confidence interval (CI) being calculated as
CI ¼ log RORð Þ± 1:96 ´ SElog RORð Þ: ð3Þ
The resulting RORs and confidence intervals were visualized for the KIs studied
experimentally (color-coded universally across the paper), with additional
commonly used KIs that have been FDA approved.
MTT viability assay. Conditionally immortalized mouse podocytes (gift from
Peter Mundel49) or tubular epithelial cells (gift from Luca Gusella50) were seeded
on clear tissue culture-treated 96-well plates. Podocytes were differentiated for
10 days at 37 °C, while tubular cells were cultured for 48 h prior to testing. Cells
were then treated with one of the selected KIs at a concentration ranging from 0.5
nM to 50,000 nM for 24 h at a final volume of 100 µl. 5 mg/ml 3-(4, 5-dimethyl-
thiazolyl-2)-2, 5-diphenyltetrazolium bromide was dissolved in PBS and sterile
filtered. During the last 4 h of drug treatment, 10 µl of MTT solution were added to
each well at 37 °C. After completion of incubation, MTT-supplemented media were
replaced with 100 µl of DMSO per well, plates were gently shaken on an orbital
shaker for one minute, and absorbance was measured at 500 nm on a Molecular
Devices DTX800 plate reader at 25 °C.
High-content image analyses (HCA). Morphometric analyses were carried out as
described previously41,51 with modifications. Conditionally immortalized podo-
cytes were seeded on black, clear-bottomed tissue culture-treated 96-well assay
plates (Corning Incorporated) or black glass-bottom 96-well assay plates (Nunc) at
a density of 800–1000 cells/well. After culturing at 37 °C for 10 days, podocytes
were treated with the appropriate drug or DMSO vehicle control (diluted at 1:1667
or more). Podocytes were fixed with 4% paraformaldehyde in PBS for 15 min at
room temperature, washed three times with PBS, permeabilized with 0.1 % Triton
X-100 for 10 min and blocked for 1 h with 5% normal goat serum supplemented
with 0.05% Triton X-100. Cells were then incubated with primary antibodies in
blocking buffer at 4 °C overnight, washed with PBS and incubated with secondary
antibodies (AlexaFluor 488, AlexaFluor 568 and/or AlexaFluor 647, Thermo
Fisher) at 1:500 dilution in blocking buffer for one hour at room temperature and
subsequently counterstained for F-actin and nucleus with ActinGreen 488 (Thermo
Fisher) and Hoechst 33342, respectively, according to manufacturer’s specifica-
tions. Image acquisition was carried out on an InCell Analyzer 2200 (GE
Healthcare) using 20× and 40× air objectives for cell and focal adhesion imaging,
respectively. Image analysis and quantification were performed using ImageJ and
Broad Institute’s CellProfiler suite52. Briefly, nuclear objects were identified in the
Hoechst 33342 channel, and the corresponding cell objects were identified using
the innate propagation algorithm of CellProfiler coupled with the contrast-
enhanced phalloidin channel to define cell boundaries. Multi-parametric analysis
was performed where at least 60 features were obtained from the four channel
images including intensity, texture, shape and size metrics. Measurements were
exported directly to csv files and subsequently analyzed using MATLAB to generate
histograms and distribution plots. In addition to the MTT assay we also used the
total nuclear counts per well as a second measure of cell viability. Detailed infor-
mation on all primary antibodies is available in Supplementary Table 5.
Immunofluorescence staining. Frozen kidney sections were fixed in 4% paraf-
ormaldehyde, permeabilized in 0.1% Triton X-100 for 10 min and blocked for one
hour with 5% normal goat serum supplemented with 0.05% Triton X-100. Sections
were incubated with the primary antibodies in blocking solution, overnight at 4 °C
(parameters for the antibodies are listed in Supplementary Table 5). Sections were
subsequently washed with PBS and incubated with secondary antibodies at 1:250
dilution in blocking buffer (AlexaFluor 568 and AlexaFluor 647, Thermo Fisher
Scientific) at one hour at room temperature. Kidney sections were then stained for
F-actin and nucleus with ActinGreen 488 (Thermo Fisher Scientific) and Hoechst
33342, respectively. Cells were then imaged on a Zeiss LSM 880 (Jena, Germany)
equipped with 20× and 40× objectives. Across all samples, same acquisition settings
were applied (laser power, gain settings, magnification, zoom, pixel size, slice
thickness and number of slices). Image quantification was performed on maximum
intensity projections of Z-stacks, on ImageJ. To obtain synaptopodin intensity/
glomeruli, regions of interest (ROI) on the corresponding channel was chosen by
using the thresholded and binarized regions of the actin channel.
Immunoblot analysis. Conditionally immortalized mouse podocytes, cultured on
10 cm culture dishes for 10 days at 37 °C and treated with vehicle control or the
selected KIs for 24 h, were lysed with 4 °C RIPA buffer (Boston Bioproducts)
supplemented with 2× HALT protease and phosphatase inhibitors (Thermo Fisher
Scientific) on ice. After measurement of protein concentration, 6× loading buffer
with SDS (Boston Bioproducts) was added, and samples were boiled at 95 °C for 5
min. After equilibrating concentrations, 35 μg of protein per sample was then
resolved in SDS-PAGE with 4–20% gradient gels (Bio-rad) and wet transferred into
nitrocellulose membranes (Bio-Rad) with a constant current of 30 mA at 4 °C
overnight. Membranes were then washed, blocked with casein blocking buffer for
one hour, incubated overnight with primary antibodies, washed with TBS buffer,
incubated with IR-fluorescence secondary antibodies (Li-Cor) for one hour,
washed with TBS buffer, and visualized on a Li-Cor Odyssey CLx imaging system.
Intensity of appropriate bands were quantified and normalized to those of loading
control bands using the Li-Cor Image Studio software suite according to manu-
facturer’s instructions. Normalized intensities from at least three independently-
run biological replicates were statistically compared using unpaired t-tests. Detailed
information on all primary antibodies is available in Supplementary Table 5. Full
size, uncropped images of all the western blots used in this study are shown in
Supplementary Fig. 20.
Phospho-tyrosine enriched proteomics. Conditionally immortalized mouse
podocytes were plated on 15 cm culture dishes at a concentration of 2000 cells per
cm2. After 10 days of differentiation at 37 °C, cells treated for 1 h with 2 μM
dasatinib or DMSO vehicle control (n= 3, each) were lysed in immunoprecipita-
tion (IP) lysis buffer containing 150 mM NaCl, 1 mM EDTA, 10% glycerol, 0.1%
Tween 20, and 50 mM HEPES pH 7.4. To enrich for tyrosine-phosphorylated
proteins, 0.5 mg total protein from each concentration-normalized lysate were
incubated with 8 μg anti-mouse ferromagnetic beads pre-coated with mouse anti-
phospho-tyrosine primary antibodies at 4 °C overnight on a rotating carousel. The
beads were washed five times with 1 M NaCl with 0.1% Tween 20 at 4 °C and then
eluted using 40 μl of 2× loading buffer (Boston Bioproducts) and boiled at 95 °C for
5 min. In order to remove contamination that could affect the liquid
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chromatography-tandem mass spectrometry (LC-MS/MS) analysis, the eluted IP
proteins were separated on 10% SDS-PAGE for in-gel trypsin digestion.
The gel lane of each sample was excised and washed with 30% ACN in 50 mM
ammonium bicarbonate prior to DTT reduction and iodoacetamide alkylation.
After in-gel trypsin digestion at 37 °C overnight, the resulting peptides were
subjected to LC-MS/MS analysis on ultimate 3000 LC system coupled with a Q
Exactive tandem mass spectrometry instrument (Thermo Fisher). In brief, the
peptides were separated by a C18 reversed phase column (75 μm× 50 cm, 2 μm,
100 Å, C18, Thermo Fisher) using a 205-min binary gradient (solvent A (2%
acetonitrile (ACN), 0.1% formic acid (FA)), solvent B (85% ACN, 0.1% FA): 10 min
gradient from 1% to 5% B followed by 165 min gradient from 5% to 30% B, 15 min
gradient from 30% to 50% B, and 15 min gradient from 50% to 95% B). The eluted
peptides were directly introduced into a nanospray Flex ion source on Q Exactive
mass spectrometry system with a spray voltage of 2.15 kV and a capillary
temperature of 275 °C. Initial spectra were acquired in a positive ion mode with the
MS mass range between m/z 400–1700. The resolution was set to 140,000 FWHM
for MS and 17,500 for MS/MS. The automatic gain control (AGC) target was set to
3 × 106 for full scan and 5 × 105 for MS/MS scan in Orbitrap mass analyzer. The
precursor isolation width was 2m/z.
The MS/MS spectra were searched against the Swiss-Prot mouse database
(16,571 sequences) using Mascot (V2.3) search engine on Proteome Discoverer
(V1.4) platform. The mass error tolerance was 10 ppm for MS and 0.1 Da for MS/
MS. Methionine oxidation, phosphorylation of tyrosine and cysteine
carbamidomethyl (IAM) modification were set as variable modifications. The
protein homologs were further grouped in Scaffold software (Proteome Software,
Inc) to remove redundancies. Acceptable protein false discovery rate cut off was
less than 1%. Dasatinib treated samples were compared to vehicle-treated control
samples using the spectra counting method16,53, and differentially expressed
proteins were identified using the Benjamini-Hochberg procedure54. Top 76
downregulated proteins (with p-values < 0.05) were unsupervised clustered using
Euclidean distance, and then connected within the human protein-protein
interactome using X2K with one intermediate node that was vetted by a minimum
of two literature sources excluding the yeast two-hybrid studies55. Gene set,
pathway and ontological enrichment was carried out using the EnrichR suite17. The
experiment was repeated twice with three biological replicates each time. Summary
results of the repeat phospho-proteomic assay were similar as shown in
Supplementary Fig. 21.
Kinome-profiling analyses. We used the publicly available kinome profiling data
from Anastassiadis et al.18 that contained inhibition profiles of 300 kinases treated
with 178 clinically approved or experimental small molecules. The dataset was first
filtered by removing all protein kinases that exhibited more than 50% residual
activity across all KIs, i.e., to remove any protein kinases with no relevance. We
then further filtered the kinome database to only retain kinases with an established
relationship to actin-related processes. For this, we used the Gene Ontology Bio-
logical Processes database, where we identified and aggregated all actin-related
terms and associated genes. We calculated mean residual activity for each drug
across the remaining kinases and visualized both individual residual kinase activ-
ities under each drug as well as the mean residual activity.
Atomic force microscope elastography. Elastography measurements and ana-
lyses were carried out as previously described56 using an Asylum MFP-3D-BIO
atomic force microscope coupled with an Olympus IX-80 inverted spinning disk
confocal microscope. Briefly, conditionally immortalized mouse podocytes were
plated on collagen type-I coated 50 mm short-profile plastic dishes (BD) and
cultured for 10 days under differentiation conditions at 37 °C. They were then
treated with 2 μM of one of the six KIs (dasatinib, imatinib, nilotinib, vandetanib,
erlotinib, bosutinib) or vehicle control for 30–45 min at 37 °C. A 0.1 N/m gold-
coated silicon nitride blunt pyramidal AFM tip (Cat #: TR400PB, Asylum) was
placed on the liquid probe holder and calibrated using the thermal noise method.
Cells, treated with DMSO (vehicle) or KIs, were placed on the AFM stage at 33 °C
(lower temperature was used during experimentation to reduce evaporation and
instrument drift; even though we did not see any statistical differences between
differentiated podocyte indentation experiments performed at 37 °C with those
performed at 33 °C, we note that this lower temperature may have a small effect on
cellular biomechanics). After 15 min of thermal equilibrium, 20 μm perinuclear
region of podocytes were probed with a resolution of 4 μm using a 6 × 6 homo-
geneous array of 4 μm deep indentations (at 8 μm/s) with a uniform trigger
threshold of 30 nm. No more than ten cells were probed for each dish, limiting the
assay time on the instrument to 45 min. Contact point and depth-dependent
pointwise apparent elastic modulus were computed from each indentation curve as
previously described57; here, we report both median Hertzian fitted elastic modulus
as the homogenized cellular elasticity measurement for the given cell and the
depth-dependent pointwise apparent elastic modulus. Since increased aberrant
virtual stiffening is a common concern for AFM elasticity measurements in thin
specimens58,59, we checked both goodness of Hertzian fit (Fig. 6a) and the depth-
dependence of our pointwise elastic modulus, which was shown to be a sensitive
marker for substrate effects60. These measurements showed that our indentations
were not affected by the substrate effect (Supplementary Fig. 14). For spatial
elastography assays with increased resolution, the above measurement protocol was
modified for a spatial resolution of 1 μm by performing an indentation array of
32 × 32 over an area of 30 × 30 μm. After the AFM assay, cells were fixed with 4%
paraformaldehyde and immunostained for paxillin and actin as described above.
The experiment was repeated four times independently whereby all drug condi-
tions were tested at each given time and the testing order of drugs were randomly
chosen.
In vivo mouse experiments. All animal received humane and ethical care in
compliance with the “Principles of Laboratory Animal Care” as outlined by the
NIH Publication No. 85-23 (revised 1985). In addition, all animal studies were
approved by the Institute for Animal Care and Use Committee at Icahn School of
Medicine at Mount Sinai. 8-week old 129S1/SvImJ mice (n= 8) from Jackson Labs
were gavaged daily with either 20 mg/kg body weight dasatinib in citrate buffer or
vehicle control for five weeks. After five weeks of daily gavages, animals were
anesthetized and perfused intraventricularly with 50 ml of sterile filtered 3% par-
aformaldehyde in PBS. The kidneys were removed and processed for histology and
electron microscopy as previously described61. Histopathological analysis was
performed by a blinded expert renal pathologist using Periodic acid–Schiff (PAS),
Hematoxylin-eosin, and Masson’s trichrome stains to evaluate general morphology
of the basement membrane, tubular morphology, and extent of fibrosis, respec-
tively. To assess the reversibility of dasatinib induced proteinuria and test our
second-hit hypothesis, 8-week old MRL/MpJ-Faslpr lupus mice (n= 8) from
Jackson Labs were gavaged daily either with 20 mg/kg body weight dasatinib in
citrate buffer or vehicle control for four weeks after which treatment was dis-
continued and animals were allowed to recover for an additional week. Urine was
collected every other day. Urine albumin was measured according to the manu-
facturer’s protocol using the mouse albumin ELISA quantitation set from Bethyl
Laboratories (Montgomery, TX), whereas urine creatinine was measured according
to the manufacturer’s protocol with the creatinine colorimetric assay kit (Cayman
Chemicals, Ann Arbor, MI).
Quantitative transmission electron microscopy. In vivo FP morphometrics were
analyzed as previously described61. Briefly, after perfusion of the fixative, kidneys
were dissected; 5 mm cubic cortical segments were cut, and further fixed with 2.0%
glutaraldehyde in 0.2 M sodium cacodylate for 48 h. The samples were then washed
with phosphate buffer and osmicated with 1% osmium tetroxide for 1 h. After
quick rinse in phosphate buffer and three 10-minute incremental ethanol dehy-
dration steps, samples were washed with propylene oxide three times and stained in
the dark with uranyl acetate-lead citrate for 1-h. They were then embedded in epon
resin, and 80 nm thin sections were prepared. Thin sections were imaged on a fully
digital Hitachi H7600 transmission electron microscope at 75 kV. Glomerular
segments were imaged at a low 2000× resolution for quantification of FP width and
at a high 20,000× resolution for visualization of the slit diaphragm architecture. For
quantification, five or more glomeruli per animal were imaged randomly over at
least two separate thin sections. The number of cell-cell junctions per linear
capillary distance was measured in a blinded fashion using Image J.
Statistical methods. For high content analysis, nonparametric Kruskal–Wallis
one-way analysis of variance (ANOVA) followed by post-hoc Tukey multiple
comparison tests were used, and a p-value of 0.001 was considered statistically
significant. For all other experiments, significance was achieved at a p-value
of 0.05. Statistical comparisons for western blots, MTT viability assays,
electron microscopic morphometry, urine albumin-creatinine ratio in wild-type
animals, and immunofluorescence staining for the in vivo experiments were
performed with unpaired t-tests. For evaluation of cellular stiffness with atomic
force microscope elastography, one-way ANOVA with post-hoc Tukey test was
used. For the timecourse evaluation of urine albumin-creatinine ratio in Lupus
mice, a two-way ANOVA with Bonferroni multiple comparison post-hoc test
was used.
All imaging experiments and high-content assays were performed with at least
three well replicates each time. Every experiment (including the animal
experiments) was repeated at least three times using brand new biological material.
Due to its high cost, phosphoproteomics experiment was repeated twice with three
independent biological replicates each time.
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
All data supporting the findings of this study are available from the corresponding author
upon reasonable request. Raw mass spectrometry proteomics data have been deposited to
the ProteomeXchange Consortium via the PRIDE partner repository with the dataset
identifier PXD011761 and [https://www.ebi.ac.uk/pride/archive/projects/PXD011761].
Code availability
All the annotated data mining and image analysis protocols and codes are available
within the supplementary information files and Azeloglu Lab GitHub page [https://
github.com/AzelogluLab], respectively.
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